treatment with recombinant human erythropoietin ( r-huepo ; epogen [ epoetin alfa ] , amgen inc , thousand oaks , ca ) rapidly corrects the anemia associated with end-stage renal disease during the acute phase of therapy and supports hematocrit levels throughout the maintenance phase .
C0700704
epogen
C0357126
epoetin alfa